Pipeline / Vascular Disease
Vein Graft Bypass
Peripheral vascular disease, narrowing and blockage of peripheral arteries as the result of plaque accumulation, affects between 8 to 12 million individuals in the U.S. and is estimated to affect over 200 million individuals worldwide. The most severe form of peripheral vascular disease, known as critical limb ischemia, carries great risk: at one year following diagnosis, 25 percent of patients will be dead and 30 percent will have undergone amputation.
The most common surgical treatment for critical limb ischemia is a vein graft procedure to bypass blocked arteries and restore blood flow. However, vein grafts fail in 30 to 50 percent of procedures, leading to amputation and mortality.
SB-030 for Prevention of Vein Graft Failure
SB-030 is in development to improve clinical outcomes following surgical vein graft procedures. SB-030 is administered locally, acting on the extracellular matrix of exposed connective tissue. In targeting responses mediated by the extracellular matrix, SB-030 aims to reduce the scarring (neointimal hyperplasia) and blood clot formation that leads to vein graft failure.
Beyond vein graft failure, SB-030 has potential applications for other types of vascular procedures, including coronary bypass and surgical intervention in late-stage kidney disease.
More information on the proof-of-concept SHIELD study of SB-030 in peripheral vascular disease can be found here.